NASDAQ:ARDS
Aridis Pharmaceuticals Inc. Stock News
$0.0608
+0.0038 (+6.67%)
At Close: May 22, 2024
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
05:30am, Tuesday, 27'th Oct 2020
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Friday, 11'th Sep 2020
Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
08:05pm, Tuesday, 11'th Aug 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported
Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to “Hold”
01:48am, Sunday, 19'th Jul 2020
Zacks Investment Research upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, �
We Think Aridis Pharmaceuticals (NASDAQ:ARDS) Can Easily Afford To Drive Business Growth
12:42pm, Wednesday, 15'th Jul 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
H.C. Wainwright Thinks Neovasc's Stock is Going to Recover - Markets
10:13am, Thursday, 02'nd Jul 2020
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Neovasc (NVCN – Research Report) today and set a price
Is the Vanguard Property ETF a good long-term investment?
03:52am, Thursday, 02'nd Jul 2020
Is the Vanguard Australian Property Securities ETF (ASX: VAP) a good long-term investment for ASX dividend income in 2020?
Cel-Sci (CVM) Receives a Buy from H.C. Wainwright - Markets
10:18am, Monday, 29'th Jun 2020
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cel-Sci (CVM – Research Report),
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novan (NOVN
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
09:30am, Friday, 26'th Jun 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, toda
Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from Northland Securities - Markets
01:21pm, Monday, 22'nd Jun 2020
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Aridis Pharmaceuticals (ARDS – Research
Nabriva (NBRV) Gets a Buy Rating from Northland Securities - Markets
11:03am, Monday, 22'nd Jun 2020
Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV – Research Report) today and set a price
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
09:30am, Monday, 22'nd Jun 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced toda
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
12:00am, Sunday, 21'st Jun 2020
Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
